SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chie ...

Core Points - Myriad Genetics, Inc. will hold its second quarter 2025 earnings conference call on August 5, 2025, at 4:30 PM ET [1] - The company's quarterly earnings will be released the same day after market close [1] - Management will provide a financial overview and business update during the call [1] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine [3] - The company develops molecular tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3] Investor Information - A live webcast of the conference call will be available on Myriad's Investor Relations website [2] - Participants can register for the call to receive a dial-in number and unique PIN [2] - An archived version of the webcast will be accessible after the call [2]

Core Insights - Athena Diagnostics, a subsidiary of Quest Diagnostics, has launched a new laboratory test service aimed at identifying genetic causes of ataxia, a group of progressive neurological disorders affecting movement and coordination [1][2]. Company Overview - Athena Diagnostics specializes in diagnostic testing for neurological diseases and offers innovative tests for conditions such as Alzheimer's disease and muscular dystrophy [7]. - Quest Diagnostics is a leading provider of diagnostic information services and has collaborated with PacBio to develop the new ataxia test using advanced sequencing technology [1][3]. Technology and Methodology - The new test utilizes PacBio's PureTarget sequencing method, which is designed to identify long repeating DNA sequences that conventional sequencing technologies may miss [2][3]. - The test will confirm initial screening results obtained through polymerase chain reaction (PCR) testing, enhancing the quality of confirmatory testing for ataxia [2][5]. Clinical Relevance - A study indicated that the PureTarget gene panel could identify specific repeating gene patterns associated with Spinocerebellar ataxia type 10, potentially guiding care decisions based on the age of disease onset [4]. - The prevalence of ataxia in children is reported to be 26 per 100,000, with 10 per 100,000 cases attributed to genetic factors [6]. Future Developments - Athena Diagnostics is exploring the development of additional tests based on PacBio technology to enhance carrier screening capabilities [3].

Core Insights - The podcast episode discusses the increasing complexities of substance use detection and care in emergency departments, emphasizing the need for rapid diagnostic testing to prevent drug overdose deaths [3][8] - Vonda McAllister, Director of Global Product Management at QuidelOrtho, highlights the importance of continuous monitoring and comprehensive toxicology screening in addressing the crisis of drug overdoses [5] Industry Trends - There is a rising prevalence of potent synthetic drugs such as fentanyl, xylazine, and nitazines, which complicates overdose presentations [8] - The limitations of Narcan (naloxone) are becoming evident, with a growing need for repeated doses due to the potency of new opioid analogs [8] - California's "Tyler's Law" mandates fentanyl testing in suspected overdose cases, reflecting a legislative response to the crisis [8] Company Overview - QuidelOrtho Corporation is a global provider of innovative diagnostic testing solutions, focusing on various health areas including infectious diseases and cardiac biomarkers [7] - The company aims to transform diagnostics into a healthier future through science, innovation, and accessibility [7]

Diagnostic testing and information services provider Quest Diagnostics (DGX 7.04%) reported fiscal 2025 second-quarter results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue hit $2.76 billion and adjusted earnings per share (EPS) came in at $2.62. These results reflect improvements across sales, margins, and operating income, with management raising its outlook for both revenue and adjusted diluted EPS. The quarter showed a strong contribution from acquisitions, balanced by mo ...

Company Overview - Myriad Genetics, Inc. is a leader in molecular diagnostic testing and precision medicine, dedicated to advancing health and well-being for all [7] - The company develops and offers molecular tests that help assess disease risk and guide treatment decisions, significantly improving patient care and lowering healthcare costs [7] Employee Experience - Myriad Genetics has received the Great Place to Work Certification for the third consecutive year, with 84% of employees affirming it as a great workplace, which is 30 percentage points higher than the average U.S. company [1][3] - The focus on inclusivity and caring is highlighted by employee resource groups that foster connection and support among employees [2] - The certification reflects the passion and dedication of Myriad's teammates, emphasizing a workplace where every employee feels connected, supported, and empowered [3] Recognition and Certification - The Great Place to Work Certification is a prestigious recognition based solely on employee feedback regarding workplace experience and trust [4] - Over 10,000 companies across 60 countries apply for this certification annually, making it a global benchmark for outstanding employee experience [4][5] - Myriad Genetics' achievement of this certification indicates its status as one of the top companies to work for, providing a positive workplace environment [3]

Core Insights - Intelligent Bio Solutions Inc. (INBS) is set to present its Pharmacokinetic (PK) study data at the ADLM 2025 Clinical Lab Expo, showcasing the effectiveness of its Intelligent Fingerprinting Drug Screening System for non-invasive drug testing [2][4]. Group 1: Study Findings - The PK study demonstrated that fingerprint sweat can accurately reflect the rate and extent of codeine found in blood and saliva, indicating its reliability for drug detection [3]. - Statistical comparisons at a 95% confidence level confirmed that fingerprint sweat serves as a dependable sample matrix for drug screening [3]. Group 2: Event Participation - Daniel Brown, Head of Clinical Affairs at INBS, will represent the company at the ADLM event, engaging with attendees and presenting the study's methodology and findings [4]. - ADLM 2025 is a significant global exposition for laboratory medicine, featuring over 300 expert speakers and more than 250 educational sessions [5]. Group 3: Company Overview - INBS's Drug Screening System is designed for accurate and efficient testing across various sectors, including construction, transportation, and manufacturing, with over 450 accounts in 24 countries [7]. - The Intelligent Fingerprinting Drug Screening System aims to revolutionize portable testing through rapid sample collection and results, making it a valuable tool for safety-critical industries [8].

Core Insights - A significant majority of Americans diagnosed with depression and/or anxiety believe mental health medications are effective, yet concerns about side effects prevent over half from taking them [1][2] - Genetic testing for mental health medications is viewed positively, with 54% of patients believing it could alleviate concerns regarding side effects [2][3] Company Overview - Myriad Genetics, Inc. is a leader in molecular diagnostic testing and precision medicine, offering the GeneSight test which analyzes how a patient's genes may influence their response to mental health medications [1][11] - The GeneSight test is recognized as a category-leading pharmacogenomic test for over 60 medications commonly prescribed for psychiatric conditions [11][12] Survey Findings - The GeneSight Mental Health Monitor survey indicates that 62% of patients whose providers did not use PGx testing wished they had been informed about it [3] - The survey also revealed that 67% of Americans believe it is socially acceptable to take medications for mental health, and 66% have a positive view of others taking such medications [8][9] Patient Experience - The case of a patient, Lisa Roberts, illustrates the practical benefits of the GeneSight test in prescribing effective medication without the lengthy trial-and-error process [5][6] - The survey results show that respondents rated the effectiveness of mental health medications similarly to medications for other chronic conditions, such as high blood pressure and high cholesterol [6]

Industry Overview - Artificial Intelligence (AI) and Machine Learning (ML) are crucial in precision oncology, enhancing decision-making through the analysis of large datasets and digital pathology [1] - The global AI in oncology market is valued at $1.92 billion in 2023, with a projected CAGR of 29.4%, reaching $11.52 billion by 2030, indicating rising investor interest [3] AI Initiatives and Developments - The National Institutes of Health (NIH) is evaluating the PRIMED-AI initiative to enhance disease diagnosis and treatment through coordinated AI/ML efforts [2] - AI models developed by NIH aim to predict cancer patients' responses to therapies, showcasing the growing integration of AI in healthcare [2] Key Players in AI-Driven Precision Oncology - NVIDIA is a significant player, providing powerful GPUs essential for AI models in imaging and drug development [5] - Palantir's Foundry platform enables comprehensive data analysis across laboratories, enhancing research capabilities [5] - Google's DeepMind, IBM Watson Health, and Microsoft's AI initiatives are also shaping the competitive landscape in healthcare [6] Investment Opportunities - BioXcel Therapeutics utilizes its proprietary AI platform, NovareAI, to expedite drug development, with a long-term expected earnings growth rate of 37.9% and projected revenue growth of 71.2% by 2025 [8][9] - Tempus AI enhances precision medicine through its algorithmic test platform, with a long-term expected earnings growth rate of 42% and projected revenue growth of 78.4% by 2025 [10][12] - Quest Diagnostics is integrating AI to improve operational efficiency and has acquired PathAI Diagnostics to advance digital pathology innovations, with a long-term expected earnings growth rate of 8.2% [13][14]